论文部分内容阅读
PURPOSE: To evaluate the clinical and volumetric improvement 1 week after an injection of intravitreal triamcinolone acetonide in eyes with diabetic macular oedema. Methods: Seven phakic eyes of seven diabetic patients diagnosed with clinically significant macular oedema were treated with a single 4-mg intravitreal injection of triamcinolone acetonide (0.1ml). LogMAR best corrected visual acuity (logMAR BCVA), best corrected reading ability (RA), and central macular thickness (CMT) with optical coherence tomography (OCT) were assessed prior and 1week subsequent to treatment. Results: Mean improvement in logMAR BCVA was 0.146 (P=0.03). Mean reduction in CMT was 150.9 μm (P=0.02, Wilcoxon signedrank test). Mean improvement in RA was 3 lines. Conclusion: Reduction in macular oedema was demonstrated on OCT at 1 week, in most cases associated with improvement in central visual function, in particular, reading ability. Total resolution of diabetic macular oedema may occur at 1 week following intravitreal steroid injection.
PURPOSE: To evaluate the clinical and volumetric improvement 1 week after an injection of intravitreal triamcinolone acetonide in eyes with diabetic macular oedema. Methods: Seven phakic eyes of seven diabetic patients diagnosed with clinically significant macular oedema were treated with a single 4-mg intravitreal injection best corrected visual acuity (logMAR BCVA), best corrected reading ability (RA), and central macular thickness (CMT) with optical coherence tomography (OCT) were assessed prior and 1week subsequent to treatment. Mean improvement in MMA BCVA was 0.146 (P = 0.03). Mean reduction in CMT was 150.9 μm (P = 0.02, Wilcoxon signedrank test). Mean improvement in RA was 3 lines. Conclusion: Reduction in macular oedema was demonstrated on OCT at 1 week, in most cases associated with improvement in central visual function, in particular, reading ability. Total resolution of diabetic macular oedema may occur at 1 week followin g intravitreal steroid injection.